Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited. However, it is noted that the German subsidiary received required approvals in Q3 FY22 and clocked sales of INR 6.1 crores, with expectations to maintain or improve volumes as more customer approvals come. For the feed market, volumes are picking up with prices stable at $12 to $14 per unit as per Feed Info. Regarding real estate monetization, ongoing efforts to monetize land and buildings, which could provide funding for CAPEX. Overall, while specific order book number

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript. The company is focused on monetizing real estate assets, particularly through a structured joint development deal for its Thane land, rather than raising funds through equity or debt. Satish Varma mentions that monetization of real estate will play a large role in funding expansions such as the Saykha CAPEX. The management indicated no immediate plans or discussions about equity or debt fundraising; emphasis is on asset monetization and internal funding. They are also focused on com

Any current/future capex/capital investment/strategic investment?

The company is investing around Rs. 40 crores in a premix plant located in Kullu to expand its product basket, expected to be operational in 8 to 10 months. They plan further expansion through a larger Saykha plant once real estate monetization is sufficiently progressed. Real estate monetization, including the Thane land development deal, is intended to fund future CAPEX especially for the Saykha facility. The Saykha CAPEX has been delayed but is a key growth driver. Management is adopting a dynamic approach, utilizing existing capacities while preparing for Saykha's launch. No immediate invo

Future growth expectations in sales/revenue/volumes?

Human Vitamin D3 demand is expected to stabilize at levels higher than pre-pandemic, supported by increasing awareness of its immunity benefits. Animal feed Vitamin D3 volumes showed a 145% increase in Q3 FY22 vs. last year but faced price pressure, indicating volume growth may continue but with cyclical price volatility. German subsidiary started sales in Q3 FY22 with INR 6.1 crores revenue; further growth depends on feed market prices and customer approvals. US subsidiary is expanding human nutrition portfolio to balance animal feed dependence, aiming for 45%-50% human nutrition share in the

Future growth expectations in earnings/operating earnings/profits/EPS?

Fermenta Biotech aspires to reach Rs. 1,000 crore turnover in the next 5 to 6 years, indicating strong top-line growth ambitions. Animal feed volumes are expected to pick up, with prices having bottomed out, suggesting margin improvement potential. German subsidiary anticipated to become more profitable as animal feed prices recover; breakeven impacted by initial inventory revaluation and trial costs. US subsidiary focusing on increasing the human nutrition segment to balance portfolio and improve stability. Real estate monetization (sale of IT buildings, land) expected to fund CAPEX for new p

IN US

Sale is live|00:00:00left today

Fermenta Biotech LtdQ4 FY23Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹338P/E: 9.7Market Cap: ₹861 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Human Vitamin D3 demand is expected to stabilize at levels higher than pre-pandemic, supported by increasing awareness of its immunity benefits.
→Animal feed Vitamin D3 volumes showed a 145% increase in Q3 FY22 vs. last year but faced price pressure, indicating volume growth may continue but with cyclical price volatility.
→German subsidiary started sales in Q3 FY22 with INR 6.1 crores revenue; further growth depends on feed market prices and customer approvals.
→US subsidiary is expanding human nutrition portfolio to balance animal feed dependence, aiming for 45%-50% human nutrition share in the US market within three years.
→Premix plant in Kullu (Rs. 40 crores investment) underway to support basket expansion ahead of Saykha plant commissioning.
→Real estate monetization expected to fund Saykha CAPEX, facilitating manufacturing growth of nutraceutical products.
→Overall, growth drivers include new capacities, geographic expansion, and product diversification in human nutrition.

Margin guidance

Category 3

→Fermenta Biotech aspires to reach Rs. 1,000 crore turnover in the next 5 to 6 years, indicating strong top-line growth ambitions.
→Animal feed volumes are expected to pick up, with prices having bottomed out, suggesting margin improvement potential.
→German subsidiary anticipated to become more profitable as animal feed prices recover; breakeven impacted by initial inventory revaluation and trial costs.
→US subsidiary focusing on increasing the human nutrition segment to balance portfolio and improve stability.
→Real estate monetization (sale of IT buildings, land) expected to fund CAPEX for new plant expansions, aiding growth.
→Premix plant expected operational in 8-10 months, diversifying product offerings and enhancing margins.
→Introduction of new products like fish oil cholesterol and Vegan D3 aimed at reducing volatility and increasing revenue.
→Current low EBITDA margins due to pricing cycles and one-time costs; margin normalization expected as demand and prices improve.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
→The company is focused on monetizing real estate assets, particularly through a structured joint development deal for its Thane land, rather than raising funds through equity or debt.
→Satish Varma mentions that monetization of real estate will play a large role in funding expansions such as the Saykha CAPEX.
→The management indicated no immediate plans or discussions about equity or debt fundraising; emphasis is on asset monetization and internal funding.
→They are also focused on completing ongoing merger processes before any major structural financial moves like a new listing on NSE.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited.
→However, it is noted that the German subsidiary received required approvals in Q3 FY22 and clocked sales of INR 6.1 crores, with expectations to maintain or improve volumes as more customer approvals come.
→For the feed market, volumes are picking up with prices stable at $12 to $14 per unit as per Feed Info.
→Regarding real estate monetization, ongoing efforts to monetize land and buildings, which could provide funding for CAPEX.
→Overall, while specific order book numbers are not stated, the company shows optimism about increasing volumes and sales in both animal feed and human nutrition segments as approvals progress and market conditions improve.

Capex plans

Yes

→The company is investing around Rs. 40 crores in a premix plant located in Kullu to expand its product basket, expected to be operational in 8 to 10 months.
→They plan further expansion through a larger Saykha plant once real estate monetization is sufficiently progressed.
→Real estate monetization, including the Thane land development deal, is intended to fund future CAPEX especially for the Saykha facility.
→The Saykha CAPEX has been delayed but is a key growth driver.
→Management is adopting a dynamic approach, utilizing existing capacities while preparing for Saykha's launch.
→No immediate involvement in construction or development—the company contributes land and receives developed carpet area in return.
→Other strategic moves include exploring value addition closer to European or American markets.

How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Fermenta Biotech Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Fermenta Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio